Poster Abstract Session:
227. Antimicrobial Pharmacokinetics and Pharmacodynamics
Saturday, October 29, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

.

Tracks: Adult ID

Presentations:
Evaluation of Extended-Interval Aminoglycoside Dosing (EIAD) in Pediatric Patients
Palak H. Bhagat, PharmD, BCPS ; Allison H. Bartlett, MD, MS ; Colleen B. Nash, M.D., M.P.H.
Population Pharmacokinetic (PPK) Analysis for Lefamulin Using Phase 1 Data and Assessment of Optimal PK Sampling Strategies (OSS) for a Phase 3 Community-Acquired Bacterial Pneumonia (CABP) Study
Li Zhang, M.D., Ph.D. ; Sujata Bhavnani, Pharm.D., M.S. ; Paul G. Ambrose, Pharm.D., FIDSA ; Wolfgang W. Wicha, M.S. ; Steve Gelone, Pharm.D. ; Christopher M. Rubino, Pharm.D.
Dosing and Pharmacokinetics of Polymyxin B in Renal Insufficiency
Visanu Thamlikitkul, MD ; Yanina Dubrovskaya, PharmD ; Pooja Manchandani, MPharm ; Thundon Ngamprasertchai, MD ; Adhiratha Boonyasiri, MD ; Vincent Tam, PharmD
Insights into the Exposure Response Relationship for Ribavirin in the Treatment of Chronic Hepatitis C Virus (HCV) infections
Brian T. Tsuji, Pharm.D. ; Charles Venuto, PhD ; Qing Ma, Ph.D. ; Robin Difrancesco, Ph.D. ; Cindy Bednasz, Pharm.D. ; Nicholas Smith, Pharm.D. ; Gene Morse, PharmD ; Andrew Talal, MD
Comparative In vivo Pharmacokinetics/Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh Infection Model Against Staphylococcus aureus
Alexander J. Lepak, M.D. ; Miao Zhao, MS ; Karen Marchillo, MLT ; Jamie Vanhecker, CVT ; Jennifer I. Smart, PhD ; Jon Bruss, MD, MSPH, MBA ; David R. Andes, M.D., FIDSA
Simplifying Piperacillin/Tazobactam (TZP) Dosing: Pharmacodynamics (PD) of Utilizing 4.5g Doses for Patients with Normal and Impaired Renal Function
Abrar Thabit, PharmD, BCPS ; Mordechai Grupper, MD ; David Nicolau, PharmD, FCCP, FIDSA ; Joseph Kuti, PharmD
No Dose Adjustment Necessary for Isavuconazole in Obese Patients
Amit Desai, PhD ; Laura Kovanda, BA ; David R. Andes, M.D., FIDSA ; Christopher Lademacher, MD ; Robert Townsend, PhD ; Marc Engelhardt, MD ; Peter Bonate, PhD
Optimization of Voriconazole Therapy Via a Validated Voriconazole Dose Modification Guideline (VDMG).
Anthony Anderson, PharmD ; Tiffany Lin, PharmD ; Dayna Mcmanus, PharmD ; Sarah Perreault, PharmD ; Michael Ruggero, PharmD ; Jeffrey Topal, MD
Brain Penetration of Isavuconazole following Single Dose Oral Administration to Wistar Rats
Anne-Hortense Schmitt-Hoffmann, PhD, PharmD ; Marlowe J. Schneidkraut, PhD ; Nkechi Azie, MD ; Robert Townsend, PhD ; Jochen Spickermann, Diplom-Chemiker, Dr. rer. nat.
A Multisite Review of Concomitant Use of Daptomycin and Statins and the Effect on CPK
Bethany Lehman, DO ; Elizabeth Neuner, PharmD ; Carlos Isada, MD
Posters
  • IDSA poster 2016 kc.pdf (820.9 kB)
  • Lack of Effect of Oritavancin on Warfarin Pharmacokinetics in Healthy Adult Subjects
    S. Eralp Bellibas, MD, PhD ; Carlos Sanabria, MD ; Brooke Lohse, BA ; Karen Fusaro, BA ; Jeff Loutit, MBChB ; Michael N. Dudley, Pharm.D.
    Clinical Evaluation of an Alternate Cefepime Dosing Protocol for Gram-Negative Bloodstream and Respiratory Infections
    Alyssa Gould, PharmD ; Kiri Rolek, PharmD ; Jayme Anderson, PharmD ; Trevor C. Van Schooneveld, MD
    Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection (BJI): tolerance, efficacy and experience with subcutaneous (SC) administration
    Tristan Ferry, MD, PhD ; Olivier Peeters, MD ; André Boibieux, MD ; Evelyne Braun, MD ; Anissa Bouaziz, MD ; Judith Karsenty, MD ; Frederic Laurent, DPharm, PhD ; Sébastien Lustig, MD, PhD ; Emmanuel Forestier, MD ; Florence Ader, MD, PhD ; Christian Chidiac, MD, PhD ; Florent Valour, MD, PhD
    Effects of Age and Sex on the Pharmacokinetics of Isavuconazole
    Amit Desai, PhD ; Donna Kowalski, MS ; Christopher Lademacher, MD ; Takao Yamazaki, PhD ; David Han, MD ; Robert Townsend, PhD
    Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Short Infusion Ceftazidime/Avibactam (CAZ/AVI) in Patients with Renal Impairment (RI)
    Andrea Boyce, PharmD ; Alexander Novin, PharmD, BCPS ; Matthew Miller, PharmD, BCPS ; Gerard Barber, RPh, MPH ; Douglas N. Fish, PharmD
    Vancomycin-Related Renal Insufficiency: Does Race Play a Role?
    Mamta Sharma, MD, FIDSA ; Kaylin Braekevelt, BS ; Pramodini Kale-Pradhan, PharmD ; Susan Szpunar, PhD ; Malak Abbas, BS ; Riad Khatib, MD
    Posters
  • Sharma IDSA final.pdf (844.2 kB)
  • Augmented Renal Clearance Using Vancomycin Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Critically-Ill Pediatric Patients
    Sean Avedissian, Pharm.D. ; Diana Zhang, Pharm.D. ; John S. Bradley, MD, FIDSA, FPIDS ; Lama Nazer, Pharm.D. ; Tri Tran, B.S. ; Austin Nguyen, B.S. ; Erin Bradley, MD ; Jeniffer Le, Pharm.D., MAS, FCCP, FCSHP, BCPS-ID
    Posters
  • ARCIDweek2016 POSTER_8_15.pdf (872.4 kB)
  • Optimizing Antimicrobial Strategies to Combat Invasive Staphylococcus epidermidis Displaying the Small Colony Variant (SCV) Phenotype
    Zackery Bulman, Pharm.D. ; Kari Mergenhagen, Pharm.D., BCPS AQ-ID ; Alan Lesse, MD, FIDSA ; Ganapathi Parameswaran, MD ; Brian T. Tsuji, Pharm.D.
    Pharmacokinetics and Safety of Ceftolozane/Tazobactam in Adolescents and Young Children with Proven or Suspected Gram-negative Infection
    Kajal Larson, PhD ; Brian Yu, PharmD ; Adedayo Adedoyin, PhD ; Jennifer A. Huntington, PharmD ; Luzelena Caro, Ph.D. ; Alan Xiao, PhD ; Dianne DeLucia, MS ; Ellie Hershberger, PharmD ; Elizabeth Rhee, MD
    Pharmacokinetic Response after Subcutaneous Administration of Ceftriaxone.
    Pieter Muntendam, MD ; Rene Myers, PhD ; Todd Shearer, PHD
    Ceftolozane/Tazobactam Clearance During In Vitro Continuous Renal Replacement Therapy (CRRT)
    Weerachai Chaijamorn, BSc (Pharmacy), BCP, BCPS ; Alexander Shaw, Pharm D ; Susan J. Lewis, PharmD ; Bruce Mueller, PharmD
    Total and Unbound Cefazolin Pharmacokinetics and Pharmacodynamics in Non-Obese and Obese Patients
    S. Christian Cheatham, PharmD ; Andrea H Stock, PharmD, BCPS ; Sara Utley, PharmD ; Maureen Campion, PharmD ; Timothy F Murrey, PharmD ; Daniel P Healy, PharmD ; Matthew F. Wack, MD ; Alicia Browning, PharmD ; Julia Jeffery, PharmD ; Eun Kyoung Chung, PharmD, PhD ; Michael Kays, PharmD, FCCP
    Comparison of AUC-guided vs trough-guided vancomycin dosing in adult patients.
    Lauren Kato, Pharm.D. ; Gilmer Youn, MD ; Emi Minejima, PharmD ; Michael Neely, MD
    Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age
    Daniel Gonzalez, PharmD, PhD ; John S. Bradley, MD, FIDSA, FPIDS ; Jeffrey Blumer, MD, PhD ; Ram Yogev, MD ; Kevin Watt, MD ; Laura James, MD ; Debra Palazzi, MD ; Varsha Bhatt-Mehta, PharmD, MS ; Janice Sullivan, MD ; Li Zhang, M.D., Ph.D. ; Jennifer Murphy, PhD ; Xilla Ussery, MD ; Sailaja Puttagunta, MD ; Michael Dunne, MD ; Michael Cohen-Wolkowiez, MD, PhD
    Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)
    Sujata Bhavnani, Pharm.D., M.S. ; Li Zhang, M.D., Ph.D. ; Christopher M. Rubino, Pharm.D. ; Justin C. Bader, Pharm.D., MBA ; Alexander J. Lepak, M.D. ; David R. Andes, M.D., FIDSA ; Robert K. Flamm, Ph.D. ; Sue K. Cammarata, M.D. ; Paul G. Ambrose, Pharm.D., FIDSA
    Emerging Candida glabrata Resistance and Echinocandin Dosing: A Call to Arms!
    Justin C. Bader, Pharm.D., MBA ; Elizabeth A. Lakota, Pharm.D., M.S. ; Sujata Bhavnani, Pharm.D., M.S. ; Paul G. Ambrose, Pharm.D., FIDSA
    Population Pharmacokinetics (PPK) of Plazomicin and Use of Therapeutic Drug Management (TDM) in Critically Ill Patients
    Scott A. Van Wart, M.S., Ph.D. ; Julie D. Seroogy, B.S. ; Michael Trang, Pharm.D. ; Lynn E. Connolly, MD, PhD ; Christopher M. Rubino, Pharm.D. ; Adrian M. Jubb, MBChB, Ph.D., FRCPath ; Sujata Bhavnani, Pharm.D., M.S. ; Valerie Riddle, M.D., FACP ; Tomoyuki Mizuno, Ph.D. ; Alexander A. Vinks, Pharm.D., Ph.D., FCP ; Alan Forrest, Pharm.D.
    Population Pharmacokinetic (PPK) Analysis for Intravenous (IV) and Oral (PO) Delafloxacin Using Data from Phase 1 Studies
    Li Zhang, M.D., Ph.D. ; Sujata Bhavnani, Pharm.D., M.S. ; Paul G. Ambrose, Pharm.D., FIDSA ; Sue K. Cammarata, M.D. ; Christopher M. Rubino, Pharm.D.
    Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Oral Lefamulin Dose Selection in the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)
    Sujata Bhavnani, Pharm.D., M.S. ; Li Zhang, M.D., Ph.D. ; Christopher M. Rubino, Pharm.D. ; Justin C. Bader, Pharm.D., MBA ; Wolfgang W. Wicha, M.S. ; Steve Gelone, Pharm.D. ; Paul G. Ambrose, Pharm.D., FIDSA
    Aminoglycoside Susceptibility Testing Breakpoint Re-Evaluations: Updates Based on the Application of Pharmacokinetics-Pharmacodynamics and Contemporary Microbiology Surveillance Data
    Sujata Bhavnani, Pharm.D., M.S. ; Paul G. Ambrose, Pharm.D., FIDSA ; David R. Andes, M.D., FIDSA ; John S. Bradley, M.D. ; William A. Craig, M.D., FIDSA ; George L. Drusano, M.D., FIDSA ; Ronald N. Jones, M.D.
    Daptomycin Plus Ceftaroline Against Daptomycin-Resistant Enterococcus faecium in a Rat Model of Experimental Endocarditis
    Daniel Smith, M.D. ; Kavindra Singh, Ph.D. ; Truc Tran, PharmD ; Cesar Arias, MD, PhD, FIDSA ; Barbara Murray, M.D.
    Increased Cardiac Risk With Concomitant Levofloxacin (LVQ) and Amiodarone (AMIO) Therapy
    Benjamin Miao, PharmD Candidate ; Luigi Brunetti, PharmD, MPH ; John Bucek, MD ; Ronald Nahass, MD, FIDSA, FSHEA
    Posters
  • LVN AMIO IDSA 10-2-16.pdf (1021.6 kB)
  • Ethambutol is a Dialysable Drug, and Drug Monitoring Ensures Safety and Therapeuticity
    Rusheng Chew, BMedSci MBBChir DTM&H DRCOG DHMSA FRACP ; Sarah Jongbloed, MBBS PhD ; Dev Jegatheesan, MBBS ; Helen Healy, MBBS PhD FRACP ; Kim Ta, BPharm ; Jacobus Ungerer, MBChB MMed MBL FRCPA ; Peter Donovan, BAppSc MBBS FRACP ; Marion L. Woods II, MD MPH FRACP FACP FAFPHM
    Posters
  • IDWeek Poster 1.pdf (210.8 kB)
  • Pharmacokinetics of a Novel Monoclonal Antibody Targeting Staphylococcal Protein A in Patients Hospitalized with S. aureus Bacteremia
    Mark E. Rupp, MD, FIDSA, FSHEA ; Michael Stecher, MD ; John Mckinnon, MD, MSc ; Norma Jung, MD ; Toan Huynh, MD
    Posters
  • 1985_IDWPOSTER.pdf (7.9 MB)
  • Ceftazidime-Avibactam Combats KPC-2 and KPC-3-Producing Klebsiella pneumoniae ST258: New Pharmacodynamic Insights into the Next Generation of β-lactam/β-lactamase Inhibitors
    Zackery Bulman, Pharm.D. ; Michael Satlin, MD ; Barry N. Kreiswirth, PhD ; Liang Chen, PhD ; Justin Lenhard, Pharm.D. ; Nicholas Smith, Pharm.D. ; Patricia Holden, B.S. ; Brian T. Tsuji, Pharm.D.
    Pharmacokinetics of Intravenous Amikacin in Intermittent Hemodialysis: Treatment of Peritoneal Dialysis Peritonitis caused by Nontuberculous Mycobacterium (NTM)
    Francine Kwee, BScH, BScPharm ; Nisha Andany, MD, FRCPC ; Jeffrey Perl, MD, SM, FRCPC ; Elizabeth Leung, PharmD, BCPS AQ-ID
    High doses of ertapenem (1g/12h) administered subcutaneously optimize the ertapemem exposure in patients with bone in joint infections (BJI): a Monte Carlo simulation stud
    Tristan Ferry, MD, PhD ; Sylvain Goutelle, DPharm, PhD ; Marie-Claude Gagnieu, DPharm ; Frederic Laurent, DPharm, PhD ; Christian Chidiac, MD, PhD ; Florent Valour, MD, PhD
    Posters
  • Poster_Erta_IDweek2016.pdf (369.5 kB)
  • Rifampin Target Attainment During Treatment of Tuberculosis Meningitis: The Role of Pharmacogenetics
    Alyssa Mezochow, MSc ; Tao Liu, BSc ; Kiran Thakur, MD ; Vijay Ivaturi, PhD ; Christopher Vinnard, MD
    PK-PD Target Attainment Analyses to Support the Selection of Extended Interval CD101 Dosing Regimens
    Elizabeth A. Lakota, Pharm.D., M.S. ; Justin C. Bader, Pharm.D., MBA ; Dirk Thye, M.D. ; Ken Bartizal, Ph.D. ; Voon Ong, PhD ; Sujata Bhavnani, Pharm.D., M.S. ; Paul G. Ambrose, Pharm.D., FIDSA ; Christopher M. Rubino, Pharm.D.
    S-649266, a Novel Siderophore Cephalosporin: Pharmacodynamic assessment by using MIC in Iron-depleted Cation-adjusted Mueller Hinton Broth (ID-CAMHB)
    Masakatsu Tsuji, Ph.D ; Tsukasa Ito-Horiyama, master’s degree ; Rio Nakamura, Bachelor of Pharmacy ; Takafumi Sato, Ph.D ; Yoshinori Yamano, Ph.D
    Posters
  • 1995_S-649266_PKPD_final.pdf (1.3 MB)
  • CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.